Sector News

Dr. Reddy’s shopping for deals up to $1B as it expands in injectable meds

March 26, 2015
Life sciences
Dr. Reddy’s Laboratories is eyeing deals as big as $1 billion to build up its portfolio of higher-end products, including generic injectable drugs, and expand its footprint in emerging markets.
 
The Hyderabad, India-based company is scouting for a range of products and buyouts–everything from dermatology and migraine treatments to new drug delivery systems and nanotech. It’s also eyeing deals that would build up its presence in Latin America, CEO G.V. Prasad told Bloomberg.
 
Dr. Reddy’s is up for a set of small acquisitions or bigger deals worth as much as $1 billion, Chief Financial Officer Saumen Chakraborty added. “I think in the next two years it will be very important for us to make some good moves on inorganic growth,” Chakraborty said.
 
Meanwhile, Dr. Reddy’s plans to ask the FDA to approve four or 5 complex injectables in the next 24 to 30 months, Chief Operating Officer Abhijit Mukherjee told Bloomberg. The Indian pharma already boasts complex products such as patches, eyedrops and topic medications, but expanding into injectables would give it some insulation against competition, plus the opportunity to charge higher prices.
 
If all goes to plan, the company will reap about 60% of its U.S. sales from complex products in three years, up from about 25% today, Chakraborty said.
 
Inking new deals and diving into injectables could also help Dr. Reddy’s weather trouble in its generic pill business. In November, the FDA slapped Dr. Reddy’s for manufacturing problems at a plant producing active ingredients for several drugs, including its knockoff version of AstraZeneca’s  heartburn med Nexium. Dr. Reddy’s has since transferred manufacturing to another site and is shooting to launch the Nexium generic by March 2016, Mukherjee said.
 
Dr. Reddy’s is not the only generics company with injectable-drugs ambitions. In 2013, Mylan snatched up Strides Arcolabs’ injectables unit Agila Specialties for $1.6 billion, adding another 200 products to its injectables portfolio and expanding its geographic footprint. Last year, Par Pharmaceutical shelled out $490 million for JHP Pharmaceuticals to beef up in generic injectables, and India’s Lupin scooped up Netherlands-based Nanomi to break into the market.
 
Jordan’s Hikma also jumped on the injectable bandwagon in 2014, paying Boehringer Ingelheim up to $300 million for injectable drugs once made at its shuttered Ben Venue plant. Hikma said at the time that it would reintroduce the products, addressing “critical supply shortages in the U.S. market” that stemmed from the plant’s quality problems.
 
By Emily Wasserman
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).